Texas is currently home to 4891 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
NCT04787744
Recruiting
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas
Conditions: Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
Register for Updates
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
NCT04786262
Recruiting
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/29/2025
Locations: Baylor Scott and White Research Institute, Dallas, Texas
Conditions: Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
Register for Updates
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
NCT04567420
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: PRiSMs Group, Laredo, Texas
Conditions: Breast Cancer
Register for Updates
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
NCT03583710
Recruiting
This phase III trial studies how well mitotane alone works compared to mitotane with cisplatin and etoposide when given after surgery in treating patients with adrenocortical cancer that has a high risk of coming back (recurrence). Cortisol can cause the growth of adrenocortical tumor cells. Antihormone therapy, such as mitotane, may lessen the amount of cortisol made by the body. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cell... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma
Register for Updates
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
NCT03471260
Recruiting
This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Neoplasm, Myelodysplastic Syndrome
Register for Updates
Anesthetics and Analgesics in Children
NCT03427736
Recruiting
The purpose of this study is to characterize the pharmacokinetic (PK) and safety profile of anesthetics and analgesics in children and adolescents.
Gender:
ALL
Ages:
Between 0 years and 17 years
Trial Updated:
07/29/2025
Locations: Dell Children's Medical Center of Texas, Austin, Texas
Conditions: Anesthesia, Pain
Register for Updates
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
NCT03295227
Recruiting
This phase I trial studies the sides effects and best dose of pembrolizumab in treating participants with thymoma or thymic cancer that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Stage III Thymoma AJCC v8, Stage IIIA Thymoma AJCC v8, Stage IIIB Thymoma AJCC v8, Stage IV Thymoma AJCC v8, Stage IVA Thymoma AJCC v8, Stage IVB Thymoma AJCC v8, Unresectable Thymic Carcinoma
Register for Updates
Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma
NCT02106988
Recruiting
The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control Stage 1 and/or 2 NK cell lymphoma. The safety of the radiation and chemotherapy combination will also be studied. This is an investigational study. Radiation and chemotherapy are FDA approved and commercially available for patients with Stage 1 and/or 2 NK cell lymphoma. The combination of these therapies given at the same time is investigational. Up to 40 patients will take part in this... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
NCT01409161
Recruiting
This phase II trial studies how well tretinoin and arsenic trioxide with or without gemtuzumab ozogamicin works in treating patients with previously untreated acute promyelocytic leukemia. Drugs used in chemotherapy, such as tretinoin and arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotoxins, such as gemtuzumab ozogamicin, may find certain cancer cells and kill the... Read More
Gender:
ALL
Ages:
10 years and above
Trial Updated:
07/29/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Promyelocytic Leukemia With PML-RARA
Register for Updates
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
NCT01371630
Recruiting
This phase I/II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating patients with acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH). Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers CalichDMH to kill them. Immunotherapy w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Burkitt-Like Lymphoma With 11q Aberration, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Burkitt Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory Burkitt Lymphoma
Register for Updates
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT00501826
Recruiting
This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Register for Updates
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Not set, Austin, Texas
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Register for Updates